PathMaker Neurosystems is a near-commercial stage neuromodulation company founded to commercialize recent advances in the development of non-invasive devices for neuronal hyperexcitability suppression that enable the treatment of patients with serious neurological disorders.  We are focused on rapidly bringing to market revolutionary products for non-invasively treating Spasticity and ALS (amyotrophic lateral sclerosis).  Based on extensive pre-clinical animal studies, recent elucidation of molecular mechanisms and published human clinical results, the Company is advancing an entirely novel treatment paradigm based on multi-site direct current stimulation (Multi-Site DCS). Our proprietary technology is able to non-invasively restore neural pathways damaged by stroke, ALS and other neurological disorders by normalizing pathway overactivity.

Connect with us on: